MiR-10a-3p as a potential non-invasive biomarker for NSCLC patients’ survival
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1029008 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR26410809.fastq.gz | Fastqsanger.gz | |||
| SRR26410810.fastq.gz | Fastqsanger.gz | |||
| SRR26410811.fastq.gz | Fastqsanger.gz | |||
| SRR26410812.fastq.gz | Fastqsanger.gz | |||
| SRR26410813.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 15 |
Similar Datasets
Project description:Lung cancer is the most currently diagnosed cancer type among adults and the most common cause of death from cancer worldwide. Poor lung cancer patients’ outcomes and survival rates demand discovery of new biomarkers for the specific, significant, and non-invasive detection of non-small cell lung cancer (NSCLC) progression. Determination of cell lines' relationship to genomic changes in tumors could be valuable for functional and therapeutic discoveries. Human cell line models with different aggressiveness statuses may play an important role in the investigation of NSCLC. In addition, miRNA expression patterns that are reliable in predicting NSCLC patients’ survival rates are highly promising cancer biomarkers. The aim of the present study was to investigate the potential of miRNA expression as biomarkers in NSCLC.
2024-11-27 | GSE245576 | GEO
Project description:Objective Lung cancer has the highest incidence and mortality rates globally, with the majority of cases classified as non-small cell lung cancer (NSCLC). Due to the absence of specific tumor biomarkers, most lung cancer cases are diagnosed at an advanced stage. Therefore, the identification of novel molecular biomarkers with high sensitivity and specificity for early diagnosis is deemed crucial for enhancing the treatment of NSCLC. Transfer RNA-derived small RNA (tsRNA) is closely associated with malignant tumors and holds promise as a potential biomarker for tumor diagnosis. This study aimed to investigate whether serum tsRNA could serve as a biomarker for NSCLC. Methods Differentially expressed tsRNAs were identified through high-throughput sequencing of serum samples obtained from patients with NSCLC and healthy individuals. Additional serum samples were collected for validation using Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR). The diagnostic performance of these tsRNAs was assessed through Receiver Operating Characteristic (ROC) Curve Analysis. Furthermore, preliminary functional exploration was undertaken through cell experiments. Results tsRNA-49-73-Glu-CTC is highly expressed in the serum of patients with NSCLC and demonstrates superior diagnostic value compared to commonly used tumor markers in clinical practice, such as Carcinoembryonic Antigen (CEA), Neuron-Specific Enolase (NSE), and Cytokeratin 19 Fragment (CYFRA). A combined diagnostic approach enhances the accuracy of NSCLC detection. Additionally, tsRNA-49-73-Glu-CTC is highly expressed in A549 cells, and transfection with a tsRNA-49-73-Glu-CTC inhibitor significantly reduces both proliferation and migration capabilities. Conclusions tsRNA-49-73-Glu-CTC has the potential to serve as a novel molecular diagnostic biomarker for NSCLC and plays a significant role in the biological processes associated with NSCLC proliferation and migration.
2025-02-18 | GSE278659 | GEO
Project description:The underlying mechanisms of miR-330-3p in the progresion of NSCLC have not been well investigated. Thus we design this expirment tying to find out the pathways and target genes involved in NSCLC metastasis.
2018-10-17 | GSE121323 | GEO
Project description:This study aimed to elucidate the role of microRNA miR-92a-3p in the pathogenesis of adenomyosis. We focused on understanding how miR-92a-3p in exosomes derived from ectopic lesions influences the behavior of endometrial cells, DRG neurons, and Human Umbilical Vein Endothelial Cells (HUVECs), and its potential as a non-invasive diagnostic biomarker. Our findings revealed that MiR-92a-3p is significantly upregulated in exosomes derived from ectopic lesions of adenomyosis. This upregulation was associated with enhanced migration and invasion capabilities in eutopic endometrial cells, DRG neurons, and HUVECs. Furthermore, the study demonstrated a significant correlation between the levels of MiR-92a-3p in urinary exosomes and the clinical symptoms of adenomyosis, suggesting its potential as a non-invasive biomarker for the disease. This study elucidates an exosomal signaling process via miR-92a-3p that drives pathological infiltration and angiogenesis to promote adenomyosis progression. Upregulated miR-92a-3p in biofluid exosomes shows promising non-invasive biomarker potential for diagnosis and monitoring of this disease. Our findings unveil novel targets and tools for improved clinical management.
2024-04-01 | GSE262302 | GEO
Project description:Gallbladder carcinoma (GBC) is the most common biliary tract malignant tumor. However, few diagnostic and prognostic biomarkers are available. Although the potential role of exosomes in the diagnosis of several tumor types has been repeatedly explored, the use of exosomal microRNAs (miRNAs) as specific biomarkers for GBC has not been systematically conducted. In this study, we identified a 5-exosomal miRNAs set that can be used to evaluate the risk of GBC through a three-step study that relies on biomarker discovery, training and validation. This biomarker set including the exosomal miR-552-3p, miR-581, miR-4433a-3p, miR-496, and miR-203b-3p.
2022-09-15 | GSE176159 | GEO
Project description:tsRNA-49-73-Glu-CTC: A Promising Serum Biomarker in NSCLC
| PRJNA1168154 | ENA
Project description:High expression of miR-494-3p have been associated with poor prognosis in non-small cell lung cancer (NSCLC). However, the role of miR-494-3p in the development and progression of NSCLC remains elusive. In this study, we found that miR-494-3p was overexpressed in both lung adenocarcinoma and lung squamous cell carcinoma in the Clinical Proteomic Tumor Analysis Consortium and Cancer Genome Atlas databases. A bioinformatic analysis revealed that representative pathways associated with cancer metastasis were enriched in the genes positively correlated with miR-494-3p expression levels, suggesting the potential involvement of miR-494-3p in aggressive properties of NSCLC. To identify potential targets of miR-494-3p, we explored genes inversely correlated with miR-494-3p in the mRNA expression datasets of NSCLC cell lines obtained from the Cancer Dependency Map. Integration of RNA sequencing analysis of NSCLC cells with miR-494-3p inhibition and a bioinformatic search of miRNA target prediction algorithms resulted in identification of SET/I2PP2A as a direct target of miR-494-3p. We found that suppression of SET/I2PP2A by miR-494-3p promoted cell migration and invasion, but not cell viability, in NSCLC cells, indicative of miR-494-3p and its downstream molecules as potential therapeutic targets in NSCLC with aggressive phenotypes.
2025-05-07 | GSE291023 | GEO
Project description:To date, the 5-year overall survival of early-stage non-small cell lung cancer (NSCLC) is still unsatisfactory at 59.8%. Therefore, reliable prognostic factors are needed. Growing evidence shows that cancer progression may depend on a double interconnection between cancer cells and the surrounding tumor microenvironment; hence, circulating molecules may represent promising markers of cancer recurrence. Here, we performed in-depth analysis of circolome-derived markers, including Exo-miRnome and peptidome in 67 radically resected NSCLCs, to identify a prognostic score. The miRnome profile selected exo-miR130a-3p as the most overexpressed in patients with relapse. Peptidome analysis identified 4 progressively more degraded forms of fibrinopeptide A (fpA) in progressing patients. Notably, the combination of exo-miR130a-3p and the greatest fpA (2-16) built a score where high-risk patients had 24 months of disease-free survival. Moreover, in vitro transfections showed that higher levels of exo-miR-130a-3p lead to a deregulation of some pathways involved in metastasis, in angiogenesis, such as in coagulation which could be linked to the FpA reduction. In conclusion, the identified risk score integrating circulating markers can help clinicians predict early-stage NSCLC patients who are more likely to relapse after initial surgery.
2022-03-16 | MSV000089072 | MassIVE
Project description:<p><strong>OBJECTIVES:</strong> High activity of Indoleamine 2,3-dioxygenase1 (IDO1) in lung cancer patients converts tryptophan (Trp), which is the essential amino acid for T cell metabolism, to kynurenine (Kyn) and consequently suppresses anti-tumor immune responses. We aimed to track the dynamics of IDO1 activity in stage III non-small cell lung cancer (NSCLC) patients who received first-line radiotherapy (RT) and explore its association with survival outcomes.</p><p><strong>MATERIALS AND METHODS:</strong> Systemic IDO1 activity was calculated by Kyn:Trp ratio. Plasma levels of Kyn and Trp in 113 thoracic RT-received stage III NSCLC patients were measured by high-performance liquid chromatography before the initiation of RT. Dynamic change of IDO1 activity was followed in 24 patients by measuring Kyn:Trp ratio before, during and after RT administration.</p><p><strong>RESULTS:</strong> In 24 patients with dynamic tracking of plasma IDO1 activity, there was no significant alterations observed among the 3 time points (Friedman test, p=0.13). The changing pattern of Kyn:Trp ratio was divided into 4 groups: decreased consistently during RT, first increased then decreased, increased consistently, first decreased then increased. Patients whose Kyn:Trp ratio kept decreasing or first increased then decreased were defined as good-change group. The good-change status was identified as an independent positive factor for overall survival (OS) and progression-free survival (PFS) (p=0.04; p=0.01) in multivariate analysis among evaluated parameters. Patients with good change showed significantly superior local control than bad-change group (p=0.01, HR=0.22). In 113 stage III NSCLC patients with pre-radiation Kyn:Trp ratio, a trend that high baseline IDO1 activity was associated with short OS was observed (p=0.079).</p><p><strong>CONCLUSION: </strong>Favorable change of IDO1 activity during RT was associated with superior OS, PFS and local control. IDO1 activity is a promising biomarker for prognosis in stage III NSCLC patients.</p>
2022-08-05 | MTBLS5267 | MetaboLights
Project description:Methanocaldococcus sp. 10A Genome sequencing
| PRJNA1246685 | ENA